abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

Diese Seite ist nicht auf Deutsch verfügbar und wird angezeigt auf English

Artikel

14 Dez 2021

Autor:
Insurance Journal

USA: Pharmaceutical company Allergan reaches $200 million settlement with State of New York, removing it from ongoing lawsuit over the opioid crisis

"Allergan Settles for $200M with New York Over Opioids", 11 Dec 2021

Pharmaceutical company Allergan Finance LLC will pay $200 million to New York state and two of its counties as part of an agreement that removes it from an ongoing state lawsuit over the opioid crisis…

As part of the agreement … Allergan did not admit to any liability.

“The settlement will provide up to $200 million to address opioid-related issues, as well as reimburse attorneys’ fees and costs that specifically account for the advanced stage of this trial,” it said. “Allergan previously made the decision to voluntarily discontinue its branded prescription opioid business, which had a minimal market share of less than 1% of nationwide prescriptions.”

The agreement with Allergan means Teva Pharmaceuticals is remaining as a manufacturing defendant in a trial that has been taking place in Suffolk County in recent months…Teva and the regional drug distribution company Anda are also defendants in a county lawsuit.

In September, the state reached an agreement with another company that had been named in the suit, Endo International. Other settlements had been reached earlier in the trial process and before it began.

The lawsuit is one of thousands filed by state and local governments, Native American tribes, unions, school districts and others seeking to hold companies in the drug industry accountable for the opioid crisis, which has been linked to more than 500,000 deaths in the U.S. in the last two decades.

Some of the biggest players in the industry, including the distributors AmerisourceBergen, Cardinal Health and McKesson and drugmakers Johnson & Johnson, Mallinckrodt Pharmaceuticals and Purdue Pharma have reached nationwide settlements with a cumulative value potentially well over $30 billion, with most of the money being directed to fight the epidemic.

But most of those deals have not been finalized.

Zeitleiste

Informationen zum Datenschutz

Diese Website verwendet Cookies und andere Web-Speichertechnologien. Sie können Ihre Datenschutzeinstellungen unten festlegen. Die Änderungen werden sofort wirksam.

Weitere Informationen über unsere Nutzung von Webspeicherung finden Sie in unserer Richtlinie zur Datennutzung und Cookies

Strictly necessary storage

ON
OFF

Necessary storage enables core site functionality. This site cannot function without it, so it can only be disabled by changing settings in your browser.

Analytics-Cookie

ON
OFF

When you access our website we use Google Analytics to collect information on your visit. Accepting this cookie will allow us to understand more details about your journey, and improve how we surface information. All analytics information is anonymous and we do not use it to identify you. Google provides a Google Analytics opt-out add on for all popular browsers.

Promotional cookies

ON
OFF

We share news and updates on business and human rights through third party platforms, including social media and search engines. These cookies help us to understand the performance of these promotions.

Ihre Privatsphäre-Einstellungen für diese Website

Diese Website verwendet Cookies und andere Web-Speichertechnologien, um Ihre Erfahrung über die notwendigen Kernfunktionen hinaus zu verbessern.